Untreated Hearing Loss Now Top Modifiable Dementia Risk Factor: Lancet Commission Update

Medically reviewed | Published: | Evidence level: 1A
The Lancet Commission on Dementia Prevention has confirmed that untreated hearing loss is the largest single modifiable risk factor for dementia, accounting for approximately 8% of attributable cases globally. The landmark ACHIEVE randomized trial found that hearing aid use reduced the rate of cognitive decline by 48% in older adults at higher risk, and large observational studies consistently show substantially lower dementia risk among hearing aid users. Leading experts now recommend hearing screening for all adults starting at age 50.
📅 Published:
Reviewed by iMedic Medical Editorial Team
📄 Neurology

Quick Facts

Dementia Risk Attributable
~8% of cases
Cognitive Decline Reduction (ACHIEVE Trial)
48% in higher-risk group
Evidence Base
Multiple large prospective studies

How Does Hearing Loss Contribute to Dementia?

Quick answer: Hearing loss accelerates cognitive decline through social isolation, reduced auditory stimulation leading to brain atrophy, and increased cognitive load as the brain struggles to process degraded sound signals.

The relationship between hearing loss and dementia has been established through multiple large prospective studies. The Lancet Commission on Dementia Prevention, most recently updated in 2024, provides strong evidence quantifying the risk. Three primary mechanisms link hearing loss to cognitive decline. First, hearing loss leads to social withdrawal and isolation, which is independently associated with accelerated cognitive decline. Second, reduced auditory input leads to structural brain changes, with research by Frank Lin's group at Johns Hopkins showing accelerated brain volume loss in individuals with untreated hearing loss compared to those with normal hearing. Third, the 'cognitive load' hypothesis posits that the brain diverts cognitive resources to process degraded auditory signals, leaving fewer resources for memory and executive function.

Large prospective studies consistently show that individuals with untreated hearing loss have roughly double the risk of developing dementia compared to those with normal hearing. A landmark study by Lin et al. (2011) following 639 adults over nearly 12 years found the association was dose-dependent: each 10 dB increase in hearing loss was associated with a 20% increased risk of dementia. Mild hearing loss approximately doubled the risk, moderate loss tripled it, and severe loss increased risk nearly fivefold. Importantly, emerging evidence suggests this risk is at least partially modifiable through hearing intervention.

Can Hearing Aids Actually Prevent Dementia?

Quick answer: The landmark ACHIEVE randomized trial showed hearing aids significantly reduced cognitive decline in older adults at higher risk, and large observational studies consistently link hearing aid use with lower dementia incidence.

The ACHIEVE (Aging and Cognitive Health Evaluation in Elders) randomized trial, led by Frank Lin at Johns Hopkins University, was the first large RCT to test whether hearing intervention could slow cognitive decline. Published in The Lancet in 2023, the trial enrolled nearly 1,000 older adults aged 70–84 with untreated hearing loss. While the overall study population did not show a statistically significant benefit, a pre-specified higher-risk subgroup — those with greater baseline cognitive vulnerability — showed that hearing aid use over 3 years reduced the rate of cognitive decline by 48% compared to a health education control. Large observational studies have also consistently found that hearing aid users have substantially lower dementia incidence than non-users.

Based on the growing body of evidence, the 2024 Lancet Commission recommends: (1) hearing screening for adults starting at age 50, (2) prompt hearing aid fitting for identified hearing loss, and (3) inclusion of hearing assessment in routine dementia risk evaluations. Addressing hearing loss at a population level could potentially prevent hundreds of thousands of dementia cases annually worldwide, according to Commission estimates. Several countries have already expanded hearing aid access in response to the evidence — notably France's '100% Santé' reform, which eliminated out-of-pocket costs for a range of hearing aids starting in 2021, significantly increasing uptake among older adults.

Frequently Asked Questions

The Lancet Commission recommends hearing screening for all adults starting at age 50, or earlier if there are risk factors such as noise exposure, family history, or diabetes. Many audiologists recommend a baseline hearing test at age 40 for comparison purposes, particularly for those with occupational noise exposure.

The evidence suggests that any device that effectively restores auditory input may be beneficial, including behind-the-ear aids, in-ear aids, and cochlear implants. The key factor appears to be consistent use — studies indicate that regular, daily hearing aid use is associated with the greatest cognitive benefit, while occasional or inconsistent use shows less benefit.

References

  1. Livingston G, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet. 2024;404(10452):572-628.
  2. Lin FR, et al. Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial. The Lancet. 2023;402(10404):786-797.
  3. Lin FR, et al. Hearing Loss and Incident Dementia. Archives of Neurology. 2011;68(2):214-220.
  4. Livingston G, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet. 2020;396(10248):413-446.